Click ‘Visit Us’ to view our clinical research webpage:
Visit Us
Learn More
Learn More
Learn More
Learn More
Learn More
Learn More
Patient Information Sheet
**NOW ENROLLING STUDIES**
AbbVie-Protocol M23-699, Indication: Lupus
Title: SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
Alumis-Protocol ESK-001-010
Title: A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patient with Systemic Lupus Erythematosus
Janssen-Protocol JNJ-77242113PSA3002
Title: A Phase 3, Multicenter, Randomized Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JAN-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis
Resolve-Protocol RSLV132-06
Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants with Sjogren’s Syndrome (SS) with Moderate to Severe Symptom Burden
AbbVie-Protocol M23-700
Title: A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)
**PENDING STUDIES**
Janssen- Protocol JNJ-77242113PSA3001
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis
PATIENT INFORMATION DOCUMENTS
New Patient Information
